PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation

Affiliations

• ¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
• ² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
• ³ Faculty of Nursing, Suzhou Vocational Health College, Suzhou, China.
• ⁴ Canglang Hospital of Suzhou, Suzhou, China.
• ⁵ Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China. liusongbai@126.com.
• ⁶ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. slxue@suda.edu.cn.
• ⁷ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. slxue@suda.edu.cn.